Skip to content

Screening and application of diagnostic molecular markers and therapeutic targets for ocular fundus neovascularization diseases

Screening and application of diagnostic molecular markers and therapeutic targets for ocular fundus neovascularization diseases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045949
Enrollment
Unknown
Registered
2021-04-30
Start date
2021-05-06
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascularization of the fundus disease

Interventions

case group:Nil
control group:Nil

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients with neovascularization of fundus oculi (diabetic retinopathy; age-related macular degeneration; choroidal neovascularization; retinal vein occlusion secondary neovascularization, etc) or patients with idiopathic macular hole, idiopathic anterior macular membrane, and age-related cataract; 2.Patients with stable vital signs, and are able to complete various treatments and follow-up; 3.Patients who have signed informed consent and are willing to complete treatment and examination; 4.Age 18 or older, regardless of gender.

Exclusion criteria

Exclusion criteria: 1.Active periocular or ocular inflammation (e.g. blepharitis, conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis).

Design outcomes

Primary

MeasureTime frame
genomics;transcriptomics;proteomics;metabonomics;lipid metabolomics;modified omics;

Countries

China

Contacts

Public ContactDing Chun

The Second Xiangya Hospital of Central South University

chunding@csu.edu.cn+86 18670792378

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026